tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Charles Duncan, 497 are a BUY (92.38%), 39 are a HOLD (7.25%), 2 are a SELL (0.37%).
Analyst Charles Duncan, currently employed at CANTOR FITZGERALD, carries an average stock price target met ratio of 49.89% that have a potential upside of 51.16% achieved within 367 days.
Charles Duncan’s has documented 1,024 price targets and ratings displayed on 76 stocks. The coverage is on Healthcare, Industrials, Technology, Basic Materials sectors.
Most recent stock forecast was given on HRMY, Harmony Biosciences Holdings at 24-Sep-2025.
Analyst best performing recommendations are on CLVS (CLOVIS ONCOLOGY).
The best stock recommendation documented was for RETA (REATA PHARMACEUTICALS) at 7/24/2023. The price target of $145 was fulfilled within 4 days with a profit of $35.33 (32.21%) receiving and performance score of 80.54.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 14-Dec-2025
$33
$12.32 (59.57%)
$37
Buy Since 16-Apr-2025
$34
$13.32 (64.41%)
$36
Buy Since 25-Nov-2019
$33
$12.32 (59.57%)
$36
Buy Since 24-Sep-2025
$31
$10.32 (49.90%)
$38
Buy Since 27-Feb-2024
$35
$14.32 (69.25%)
$41
What Year was the first public recommendation made by Charles Duncan?
